Quick Answer
Structure Therapeutics Inc. reported Operating Income Loss of -$176.56 million for the year ending 2025.
- Structure Therapeutics Inc. showed a decrease of -11.6% in Operating Income Loss from 2024 to 2025.
- This data is from Structure Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$12.95 million | Q2 2022: -$13.96 million | Q3 2022: -$12.69 million | Q1 2023: -$19.65 million | Q2 2023: -$25.99 million | Q3 2023: -$26.15 million | Q1 2024: -$32.02 million | Q2 2024: -$33.32 million | Q3 2024: -$45.84 million | Q1 2025: -$56.31 million | Q2 2025: -$70.45 million | Q3 2025: -$73.79 million.
- Over the full 4 years of available data (2022 to 2025), Structure Therapeutics Inc.'s Operating Income Loss has declined by 235.9%.
- Historical annual values: Fiscal year 2025: -$176.56 million | Fiscal year 2024: -$158.23 million | Fiscal year 2023: -$102.78 million | Fiscal year 2022: -$52.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: